"Initiation of non-GLP toxicology and pharmacokinetic studies - Q3 2020
Expansion of Deoxymab platform applications (eg nanoparticles) - Q3 2020
Completion of stable cell line development - Q4 2020"
These are some of the near term initiatives identified in the Investor Presentation. Can anyone advise me if the year 2020 is the financial year or the calendar year. If it's financial year we should probably get an update in the not too distant future.
Ann: Investor Presentation - June 2020, page-4
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 2053666 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 3325244 | 5 |
View Market Depth
| Last trade - 16.12pm 19/08/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable